Date: 27 Jan 2012

Allogenic Mesenchymal Stem Cells in Experimental Ischaemic Stroke: Translation to the Clinic?

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Currently, only intravenous thrombolysis has been shown to be effective after ischaemic stroke. Therefore, new therapies need to be found that protect and repair the neurovascular unit after ischaemic brain damage. Cell therapy provides a good alternative for stroke treatment due to enhanced neurological recovery. Several studies have suggested that mesenchymal stem cells are appropriate for clinical use, demonstrating safety, feasibility and efficacy. However, more information about their mechanisms of action and response is needed, as well as other important data such as the appropriate cell type, timing of administration, cell delivery route and optimal dose in animal models for translational applications. This review describes recent progress in cell-based therapy, focusing on mesenchymal stem cells (bone marrow and adipose tissue) in experimental animal models and clinical trials, for the treatment of stroke.